Harbin Zhenbao Pharmaceutical

Harbin Zhenbaodao Pharmaceutical is a prominent Chinese pharmaceutical enterprise specializing in the research, development, manufacturing, and commercialization of Traditional Chinese Medicine (TCM), chemical generics, and innovative biological drugs. The company is widely recognized for its flagship product, Shuxuetong Injection, which holds a significant market share in the treatment of cardiovascular and cerebrovascular diseases in China. In recent years, Zhenbaodao has aggressively expanded its R&D focus toward high-tech sectors, including innovative small molecules and monoclonal antibodies for oncology and anti-infective indications. Headquartered in Harbin, the company operates several large-scale GMP-certified production bases and maintains a robust domestic distribution network. It is listed on the Shanghai Stock Exchange and continues to integrate modern biotechnology with traditional pharmacological wisdom.